Preliminary Effects of Renal Denervation With Saline Irrigated Catheter on Cardiac Systolic Function in Patients With Heart Failure: A Prospective, Randomized, Controlled, Pilot Study

被引:41
作者
Chen, Weijie [1 ]
Ling, Zhiyu [1 ]
Xu, Yanping [1 ]
Liu, Zengzhang [1 ]
Su, Li [1 ]
Du, Huaan [1 ]
Xiao, Peilin [1 ]
Lan, Xianbin [1 ]
Shan, Qijun [2 ]
Yin, Yuehui [1 ]
机构
[1] Chongqing Med Univ, Affiliated Hosp 2, Dept Cardiol, Chongqing 400010, Peoples R China
[2] Nanjing Med Univ, Affiliated Hosp 1, Dept Cardiol, Nanjing, Jiangsu, Peoples R China
关键词
heart failure; renal denervation; PLASMA NOREPINEPHRINE; ABLATION; SYSTEM; TRIAL;
D O I
10.1002/ccd.26475
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To assess efficacy and safety of renal denervation (RDN) for heart failure (HF). Background: RDN has been demonstrated to be an effective method in lowing overactive sympathetic nerve. However, it's feasibility and efficacy for HF is unclear. Methods: In this randomized, controlled pilot study, patients with HF were randomly assigned in 1: 1 ratio to undergo RDN plus optimal medical therapy (RDN group) or only optimal medical therapy (control group). Before randomization, patients received optimal medical therapy at least half a year. Primary efficacy end point was the change in LVEF over six months; secondary efficacy end points were the change in six-minute walk distance and SF-36 Health Survey scores over six months. Results: Up to Apr 2015, sixty symptomatic HF patients were successfully enrolled into study. Thirty patients were randomly assigned to RDN group and 30 patients were randomly assigned to control group. All patients completed six months follow up. During follow up, no severe adverse events were observed. Blood pressure was stable in both groups. Patients in RDN group had shown a significant improvement in LVEF (P< 0.001), SMWD (P=0.043), NYHA class (P < 0.001), NT-proBNP (P < 0.001) and office heart rate (P=0.008). Compared with control group, RDN patients were associated with significant improvement in all domains of SF-36 but bodily pain (P=0.74). No significant change in estimate glomerular filtration nor complication of renal artery stenosis were observed. Conclusions: Results imply that RDN could be safely applied to treatment of HF and probably improve cardiac systolic function and patients' quality of life. (C) 2016 Wiley Periodicals, Inc.
引用
收藏
页码:E153 / E161
页数:9
相关论文
共 28 条
  • [1] A Controlled Trial of Renal Denervation for Resistant Hypertension
    Bhatt, Deepak L.
    Kandzari, David E.
    O'Neill, William W.
    D'Agostino, Ralph
    Flack, John M.
    Katzen, Barry T.
    Leon, Martin B.
    Liu, Minglei
    Mauri, Laura
    Negoita, Manuela
    Cohen, Sidney A.
    Oparil, Suzanne
    Rocha-Singh, Krishna
    Townsend, Raymond R.
    Bakris, George L.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (15) : 1393 - 1401
  • [2] PLASMA NOREPINEPHRINE AS A GUIDE TO PROGNOSIS IN PATIENTS WITH CHRONIC CONGESTIVE HEART-FAILURE
    COHN, JN
    LEVINE, TB
    OLIVARI, MT
    GARBERG, V
    LURA, D
    FRANCIS, GS
    SIMON, AB
    RECTOR, T
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1984, 311 (13) : 819 - 823
  • [3] The annual global economic burden of heart failure
    Cook, Christopher
    Cole, Graham
    Asaria, Perviz
    Jabbour, Richard
    Francis, Darrel P.
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2014, 171 (03) : 368 - 376
  • [4] ATS statement: Guidelines for the six-minute walk test
    Crapo, RO
    Casaburi, R
    Coates, AL
    Enright, PL
    MacIntyre, NR
    McKay, RT
    Johnson, D
    Wanger, JS
    Zeballos, RJ
    Bittner, V
    Mottram, C
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2002, 166 (01) : 111 - 117
  • [5] First-in-man safety evaluation of renal denervation for chronic systolic heart failure: Primary outcome from REACH-Pilot study
    Davies, Justin E.
    Manisty, Charlotte H.
    Petraco, Ricardo
    Barron, Anthony J.
    Unsworth, Beth
    Mayet, Jamil
    Hamady, Mohamad
    Hughes, Alun D.
    Sever, Peter S.
    Sobotka, Paul A.
    Francis, Darrel P.
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2013, 162 (03) : 189 - 192
  • [6] Reliability, validity, and responsiveness of the six-minute walk test in patients with heart failure
    Demers, C
    McKelvie, RS
    Negassa, A
    Yusuf, S
    [J]. AMERICAN HEART JOURNAL, 2001, 142 (04) : 698 - 703
  • [7] Illusions of truths in the Symplicity HTN-3 trial: generic design strengths but neuroscience failings
    Esler, Murray
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION, 2014, 8 (08) : 593 - 598
  • [8] Go AS, 2014, CIRCULATION, V129, pE28, DOI 10.1161/01.cir.0000441139.02102.80
  • [9] Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study
    Krum, Henry
    Schlaich, Markus P.
    Sobotka, Paul A.
    Boehm, Michael
    Mahfoud, Felix
    Rocha-Singh, Krishna
    Katholi, Richard
    Esler, Murray D.
    [J]. LANCET, 2014, 383 (9917) : 622 - 629
  • [10] Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study
    Krum, Henry
    Schlaich, Markus
    Whitbourn, Rob
    Sobotka, Paul A.
    Sadowski, Jerzy
    Bartus, Krzysztof
    Kapelak, Boguslaw
    Walton, Anthony
    Sievert, Horst
    Thambar, Suku
    Abraham, William T.
    Esler, Murray
    [J]. LANCET, 2009, 373 (9671) : 1275 - 1281